<?xml version="1.0" encoding="UTF-8"?><rss version="2.0" xmlns:content="http://purl.org/rss/1.0/modules/content/"><channel><title>米内网 | wechat-feeds</title><link>http://MjM5NzQ4MTg2MQ.favicon.privacyhide.com/favicon.ico</link><description>米内网是中国领先的集医药健康产业研究、医院市场研究、零售市场研究、商业渠道研究、互联网在线医药健康信息服务于一体的综合性专业信息服务平台。目前拥有七项数据分析技术获国家专利，每月收集数据3000多万条，有63个专业数据库为医药健康行业服务。</description><managingEditor> (hellodword)</managingEditor><pubDate>Mon, 05 Apr 2021 10:11:48 +0800</pubDate><image><url>http://MjM5NzQ4MTg2MQ.favicon.privacyhide.com/favicon.ico</url><title>米内网 | wechat-feeds</title><link>http://MjM5NzQ4MTg2MQ.favicon.privacyhide.com/favicon.ico</link><width>64</width><height>64</height></image><item><title>2020年全球抗体药物市场超$1500亿，五大靶点“聚宝盆”出炉，国内PD-1/PD-L1翻了TNFα的车？</title><link>https://mp.weixin.qq.com/s/2cVkefv14C3c8u_5lthMWw</link><description></description><content:encoded><![CDATA[2020年全球抗体药物市场超$1500亿，五大靶点“聚宝盆”出炉，国内PD-1/PD-L1翻了TNFα的车？]]></content:encoded><pubDate>Mon, 05 Apr 2021 07:57:01 +0800</pubDate></item><item><title>新药研发道阻且长，百奥泰并未言败</title><link>https://mp.weixin.qq.com/s/eow07Ziorb4vzB4YuekGhQ</link><description></description><content:encoded><![CDATA[新药研发道阻且长，百奥泰并未言败]]></content:encoded><pubDate>Sun, 04 Apr 2021 07:57:39 +0800</pubDate></item><item><title>3月CDE：46个存量品种过评，4个1类新药、6个首仿获批；这三个重磅品种申报新适应症上市</title><link>https://mp.weixin.qq.com/s/owIeQSvW9-pVVB1-pGd1WQ</link><description></description><content:encoded><![CDATA[3月CDE：46个存量品种过评，4个1类新药、6个首仿获批；这三个重磅品种申报新适应症上市]]></content:encoded><pubDate>Sun, 04 Apr 2021 07:57:39 +0800</pubDate></item><item><title>10个药品遭重点监控！知名药企被重罚2千万，信立泰、豪森……43个药品采购“叫停”</title><link>https://mp.weixin.qq.com/s/eKOLXnHW9kmmJGHlHwQWBA</link><description></description><content:encoded><![CDATA[10个药品遭重点监控！知名药企被重罚2千万，信立泰、豪森……43个药品采购“叫停”]]></content:encoded><pubDate>Sat, 03 Apr 2021 07:55:11 +0800</pubDate></item><item><title>一季度医药股TOP20！恒瑞、迈瑞对飚5000亿市值，片仔癀稳居中药股一哥，CRO三巨头亮眼</title><link>https://mp.weixin.qq.com/s/Aw5OQ5xJSz2GfZsmNMbHBQ</link><description></description><content:encoded><![CDATA[一季度医药股TOP20！恒瑞、迈瑞对飚5000亿市值，片仔癀稳居中药股一哥，CRO三巨头亮眼]]></content:encoded><pubDate>Fri, 02 Apr 2021 16:46:08 +0800</pubDate></item><item><title>【瞩目】国产第3家，倍特拿下6亿抗血栓药！口服降糖药抢首仿</title><link>https://mp.weixin.qq.com/s/fNHE0TMUbZhuqWqRmHxsoQ</link><description></description><content:encoded><![CDATA[【瞩目】国产第3家，倍特拿下6亿抗血栓药！口服降糖药抢首仿]]></content:encoded><pubDate>Fri, 02 Apr 2021 16:46:08 +0800</pubDate></item><item><title>【关注】正大天晴、齐鲁、豪森……围攻7亿抗肿瘤药！原研药再受冲击</title><link>https://mp.weixin.qq.com/s/9tiAxnk-vlG4uwWw_PtNZw</link><description></description><content:encoded><![CDATA[【关注】正大天晴、齐鲁、豪森……围攻7亿抗肿瘤药！原研药再受冲击]]></content:encoded><pubDate>Fri, 02 Apr 2021 16:46:08 +0800</pubDate></item><item><title>【获批】浙江药企入局100亿重磅品种！华润、鲁抗9家紧跟而至</title><link>https://mp.weixin.qq.com/s/_ZV-bddz8UdCroPdUnX6iw</link><description></description><content:encoded><![CDATA[【获批】浙江药企入局100亿重磅品种！华润、鲁抗9家紧跟而至]]></content:encoded><pubDate>Fri, 02 Apr 2021 16:46:08 +0800</pubDate></item><item><title>20款吸入剂厉害了！8个1类新药、20个首仿来袭，正大天晴亮了，成都倍特发力</title><link>https://mp.weixin.qq.com/s/1aGF8aFjIavollO_lu3GcQ</link><description></description><content:encoded><![CDATA[20款吸入剂厉害了！8个1类新药、20个首仿来袭，正大天晴亮了，成都倍特发力]]></content:encoded><pubDate>Thu, 01 Apr 2021 16:06:30 +0800</pubDate></item><item><title>【喜讯】符合第五批集采品种注射用更昔洛韦，普利制药再下一城获意大利批准</title><link>https://mp.weixin.qq.com/s/3r7ppeypOEePa3U5q56aiQ</link><description></description><content:encoded><![CDATA[【喜讯】符合第五批集采品种注射用更昔洛韦，普利制药再下一城获意大利批准]]></content:encoded><pubDate>Thu, 01 Apr 2021 16:06:30 +0800</pubDate></item><item><title>【瞩目】这家药企开挂了，两款创新药接连获批</title><link>https://mp.weixin.qq.com/s/MKv-yG1OpAnaKcVXrAu2Fw</link><description></description><content:encoded><![CDATA[【瞩目】这家药企开挂了，两款创新药接连获批]]></content:encoded><pubDate>Thu, 01 Apr 2021 16:06:30 +0800</pubDate></item><item><title>【关注】助力疼痛康复，藏医药蓄势待发</title><link>https://mp.weixin.qq.com/s/TobKddSlq-Q28m17x0yS0A</link><description></description><content:encoded><![CDATA[【关注】助力疼痛康复，藏医药蓄势待发]]></content:encoded><pubDate>Thu, 01 Apr 2021 16:06:30 +0800</pubDate></item><item><title>中成药TOP20出炉！扬子江、步长……17个独家产品霸屏，天士力、康缘1类新药来袭</title><link>https://mp.weixin.qq.com/s/mP_IoURi0iWVujrMX5UoKw</link><description></description><content:encoded><![CDATA[中成药TOP20出炉！扬子江、步长……17个独家产品霸屏，天士力、康缘1类新药来袭]]></content:encoded><pubDate>Wed, 31 Mar 2021 16:30:40 +0800</pubDate></item><item><title>【市场】8亿注射剂苑东首家过评，12个品种已过评</title><link>https://mp.weixin.qq.com/s/rbnbiVUQE8fv6ifeafT-vg</link><description></description><content:encoded><![CDATA[【市场】8亿注射剂苑东首家过评，12个品种已过评]]></content:encoded><pubDate>Wed, 31 Mar 2021 16:30:40 +0800</pubDate></item><item><title>【瞩目】科伦将拿下$6亿重磅乙肝药</title><link>https://mp.weixin.qq.com/s/R26DLbip00ONMAzpWqeG_Q</link><description></description><content:encoded><![CDATA[【瞩目】科伦将拿下$6亿重磅乙肝药]]></content:encoded><pubDate>Wed, 31 Mar 2021 16:30:40 +0800</pubDate></item><item><title>【重磅】信立泰发威！8款创新药围攻心脑血管市场</title><link>https://mp.weixin.qq.com/s/6BygA9HR1qWAd6GtwzIGeg</link><description></description><content:encoded><![CDATA[【重磅】信立泰发威！8款创新药围攻心脑血管市场]]></content:encoded><pubDate>Wed, 31 Mar 2021 16:30:40 +0800</pubDate></item><item><title>龙头易主，创新药“神助攻”恒瑞封王！国产贴膏剂逼退原研，齐鲁新药来了</title><link>https://mp.weixin.qq.com/s/75e_aMvxWDIxE2N_4JplSg</link><description></description><content:encoded><![CDATA[龙头易主，创新药“神助攻”恒瑞封王！国产贴膏剂逼退原研，齐鲁新药来了]]></content:encoded><pubDate>Tue, 30 Mar 2021 15:48:44 +0800</pubDate></item><item><title>【重磅】成都倍特新药将获批！搅局200亿抗病毒药物市场</title><link>https://mp.weixin.qq.com/s/2ZNT3Zv9CHk6Q6Abjgqfew</link><description></description><content:encoded><![CDATA[【重磅】成都倍特新药将获批！搅局200亿抗病毒药物市场]]></content:encoded><pubDate>Tue, 30 Mar 2021 15:48:44 +0800</pubDate></item><item><title>【瞩目】35亿抗哮喘药，这家广州药企将强势入局</title><link>https://mp.weixin.qq.com/s/wcKWcxZOqmwcARweMHfnjQ</link><description></description><content:encoded><![CDATA[【瞩目】35亿抗哮喘药，这家广州药企将强势入局]]></content:encoded><pubDate>Tue, 30 Mar 2021 15:48:44 +0800</pubDate></item><item><title>【火爆】好医生、科伦领军20亿中药大品种，京新要出新招？</title><link>https://mp.weixin.qq.com/s/QjovntB66_6i4qho1_yAfw</link><description></description><content:encoded><![CDATA[【火爆】好医生、科伦领军20亿中药大品种，京新要出新招？]]></content:encoded><pubDate>Tue, 30 Mar 2021 15:48:44 +0800</pubDate></item></channel></rss>